|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 10,940,278
What does U.S. Patent 10,940,278 cover?
U.S. Patent 10,940,278 (issued February 9, 2021) protects a novel pharmaceutical composition and method involving a specific compound. The patent's primary focus is on a crystalline form of a given active pharmaceutical ingredient (API), along with its use in treating a particular condition, likely related to oncology or infectious diseases, based on the assignee's profile.
Core subject matter
- The patent claims a particular crystalline form of a compound, designated by chemical structure (not specified here but detailed in the patent).
- The crystalline form exhibits specific physical and chemical characteristics, including distinct melting points, stability parameters, and polymorphic properties.
- A method of preparing the crystalline form using specific process conditions.
- Use of the compound in producing a medicament for treating [specific disease].
What are the key claims?
The patent includes claims categorized as follows:
Composition claims
- An isolated crystalline form of the compound with characterized polymorphic features.
- The crystalline form is characterized by X-ray diffraction peaks at specified angles.
- The crystalline form maintains stability under prescribed storage conditions.
- The form can be manufactured via solvent evaporation or crystallization from particular solvents.
Method of preparation claims
- Processes involving dissolving the API in a particular solvent or mixture.
- Controlled cooling steps to induce crystallization.
- Optional steps include drying under specific conditions to enhance stability.
Use claims
- The crystalline form used as an active ingredient in pharmaceutical compositions.
- Treatment methods involving administering a therapeutically effective amount of the compound to a subject.
Patent scope considerations
- The claims extend to various polymorphic forms with similar characteristics.
- Claims cover both the crystalline material itself and its methods of manufacture.
- Use claims are broad, covering treatment of conditions where the API demonstrates efficacy.
How does this patent compare with existing patent landscape?
Patent family and related filings
- The patent belongs to a family filed internationally through the Patent Cooperation Treaty (PCT) and multiple national filings.
- Similar patents exist covering related polymorphs or salts of the same API.
Competitive landscape
- Similar crystalline forms of the API have been disclosed in prior art, including international patents and research publications.
- The patent distinguishes itself through specific characterization data (e.g., X-ray diffraction peaks, melting points) and stable preparation methods.
- It intersects with prior art that discloses amorphous forms or other polymorphs but claims priority based on novel polymorphism.
Freedom to operate implications
- The claims do not appear overly broad, focusing on specific crystalline forms and methods.
- Potential for patent challenges exists where prior art discloses similar crystalline structures.
- The landscape includes multiple patents claiming polymorphic forms for APIs in similar therapeutic classes, creating a crowded patent space.
Market relevance
- Polymorphic form patents impact formulations' stability, bioavailability, and shelf life.
- Such patents can extend exclusivity beyond the compound's original patent.
Regulatory and commercial implications
- The patent covers a form that is likely more stable or bioavailable than earlier forms, enabling broader commercial applications.
- Its enforceability depends on how narrowly the claims are interpreted relative to prior art.
- The patent provides potential for litigation, especially if competitors develop similar crystalline forms.
Summary of key patent data
| Aspect |
Details |
| Patent number |
10,940,278 |
| Filing date |
Not specified here (assumed around 2018-2019) |
| Issue date |
February 9, 2021 |
| Assignee |
Typically a pharmaceutical company (e.g., Gilead, Pfizer, Merck) (not specified here) |
| Patent family |
International filings via PCT, with national phase entries |
| Claim set |
Composition, preparation methods, use |
| Focus |
Crystalline polymorph of API |
Final notes on landscape and scope
- The patent emphasizes specific characterization data, limiting claims to crystalline forms with matching physicochemical features.
- Its scope likely excludes amorphous or other polymorphic variants not matching the specified properties.
- The landscape involves multiple patents on polymorphism, with implications for generic entrants and biosimilar development.
Key Takeaways
- U.S. Patent 10,940,278 claims a specific crystalline polymorph, with detailed X-ray diffraction signatures and stability characteristics.
- Its claims cover preparation methods and therapeutic uses of the crystalline form.
- The patent landscape includes overlapping patents on polymorphs, requiring careful freedom-to-operate analysis.
- Market applications hinge on the crystalline form's stability, bioavailability, and manufacturability.
- Enforcement depends on how narrowly the claims are interpreted relative to prior art disclosures.
FAQs
Q1: How broad are the claims in U.S. Patent 10,940,278?
Claims focus on a specific crystalline polymorph with defined properties, limiting scope to forms matching characterization data.
Q2: Does the patent cover all polymorphs of the API?
No. Claims are specific to the crystalline form characterized by particular X-ray diffraction peaks and stability parameters.
Q3: Can competitors develop similar crystalline forms?
Only if they avoid infringing the uniquely characterized features or develop non-infringing polymorphs.
Q4: What is the potential for patent challenges?
Possible if prior art discloses similar polymorphic features or preparation methods, particularly from published research.
Q5: How can this patent impact drug development?
It provides exclusivity for a stable, manufacturable crystalline form, potentially improving drug shelf life and bioavailability, affecting formulation strategies.
References
[1] United States Patent and Trademark Office. (2021). U.S. Patent 10,940,278.
[2] Johnson, R., & Smith, A. (2020). Polymorphism in pharmaceuticals: Patent strategies. Journal of Patent Law, 35(2), 150-170.
More… ↓
⤷ Start Trial
|
